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Background. Pentavalent antimonials (SbV) are the first-line chemotherapy for American tegumentary leish-
maniasis (ATL). There are, however, reports of the occurrence of treatment failure with these drugs. Few studies
in Latin America have compared the response to SbV treatment in ATL caused by different Leishmania species.
Methods. Clinical parameters and response to SbV chemotherapy were studied in 103 patients with cutaneous
leishmaniasis (CL) in Peru. Leishmania isolates were collected before treatment and typed by multilocus polymerase-
chain-reaction restriction fragment–length polymorphism analysis.
Results. The 103 isolates were identified as L. (Viannia) peruviana (47.6%), L. (V.) guyanensis (23.3%), L.
(V.) braziliensis (22.3%), L. (V.) lainsoni (4.9%), L. (Leishmania) mexicana (1%), and a putative hybrid, L. (V.)
braziliensis/L. (V.) peruviana (1%). L. (V.) guyanensis was most abundant in central Peru. Of patients infected with
the 3 former species, 21 (21.9%) did not respond to SbV chemotherapy. The proportions of treatment failure (after
12 months of follow-up) were 30.4%, 24.5%, and 8.3% in patients infected with L. (V.) braziliensis, L. (V.) peruviana,
and L. (V.) guyanensis, respectively. Infection with L. (V.) guyanensis was associated with significantly less treatment
failure than L. (V.) braziliensis, as determined by multiple logistic regression analysis (odds ratio, 0.07 [95%
confidence interval, 0.007–0.8]; ).Pp .03
Conclusions. Leishmania species can influence SbV treatment outcome in patients with CL. Therefore, parasite
identification is of utmost clinical importance, because it should lead to a species-oriented treatment.
American tegumentary leishmaniasis (ATL) is a para-
sitic protozoan disease that is endemic in most coun-
tries of Latin America. It is characterized by a significant
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clinical pleomorphism, which has been related to both
the infecting Leishmania species and the host immune
response [1, 2]. This complicates epidemiological mon-
itoring and, eventually, clinical management.
This is well illustrated by the situation in Peru. In
this country, 3 species are predominant and are of ep-
idemiological importance: L. (Viannia) braziliensis, L.
(V.) peruviana, and L. (V.) guyanensis [3, 4]. The 3
species cause cutaneous lesions, but the respective clin-
ical evolution is characterized by a gradient of severity:
(1) in L. (V.) peruviana infection, lesions generally re-
main small and are self-healing [5, 6]; (2) lesions caused
by L. (V.) guyanensis may develop into diffuse cuta-
neous leishmaniasis (CL), which is characterized by dis-
seminated nodular lesions that fail to heal spontane-
ously and that reappear after the cessation of treatment
[1, 2]; and (3) L. (V.) braziliensis metastasize in up to
10% of cases [7], resulting in mutilating mucosal lesions
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(known as “espundia”). L. (V.) peruviana is mostly encountered
in the rural Andean and inter-Andean valleys (between 1000
and 3000 m above sea level), whereas the 2 other species are
both endemic in sylvatic regions. However, this epidemiological
picture can be affected by environmental changes and human
migrations [8].
Chemotherapy is the main control strategy for leishmaniases,
and pentavalent antimonials (SbV) are the first-line drugs. Un-
fortunately, the increasing trend of treatment failure docu-
mented in several field sites is now challenging the clinical value
of SbV therapy [9]. Studies conducted in Latin America have
reported a range of efficacies of this drug against CL: 7% treat-
ment failure in Bolivia [10], 16% in Brazil [11], and up to 39%
in Colombia [12]. The identification of the factors associated
with chemotherapy failure would allow better clinical man-
agement of patients.
Concerning the role played by different Leishmania species
in the chemotherapeutic response of ATL, reports are scanty.
Here, we demonstrate that Peruvian patients infected with L.
(V.) braziliensis and L. (V.) peruviana respond similarly to SbV
treatment, presenting a comparably high prevalence of treat-
ment failure, whereas patients infected with L. (V.) guyanensis
are much more responsive to SbV therapy. The epidemiological
and clinical implications of our result are discussed.
PATIENTS, MATERIALS, AND METHODS
Treatment and follow-up. Peruvian patients with a clinical
diagnosis of leishmaniasis were recruited into the Leishnatdrug-
R study between November 2001 and December 2004 at the
Instituto de Medicina Tropical “Alexander von Humboldt,” a
national reference center for patients with leishmaniasis. The
Leishnatdrug-R study was conducted to assess the occurrence
of natural resistance among Leishmania isolates obtained from
patients who either responded to treatment or experienced
treatment failure with SbV (20 mg/kg/day intravenous SbV for
20 days [13]). Patients were interviewed to identify the most
probable geographic origin of infection. They were treated with
generic sodium stibogluconate (SSG) from Colombia (Viteco
SA; ) or India (Albert David Ltd.; ), dependingnp 80 np 23
on drug availability. All used batches contained the recom-
mended SbV concentration (quality control was performed by
the International Dispensary Association). Patients received an-
timonial treatment under supervision and attended follow-up
visits 1, 3, and 6 to 12 months after treatment. Patients with
treatment failure received either (1) a repeat course of anti-
monials with or without topical imiquimod (Aldara; 3M Phar-
maceuticals) or (2) intravenous amphotericin B (amphotericin
B deoxycholate; Bristol-Myers Squibb).
Only patients with a first diagnosis of CL without concom-
itant mucosal involvement, who received 20 doses of anti-
monials, and who were followed for 6 months were included
in the present study. Written, informed consent was obtained
from all patients or their parents or guardians. Research pro-
tocols complied with national and international ethics policies.
The human experimentation guidelines of the Institute of Trop-
ical Medicine Antwerp were followed. Ethics clearance was ob-
tained from the ethical committees of the Universidad Peru-
ana Cayetano Heredia and the Institute of Tropical Medicine
Antwerp.
Definition of clinical outcomes. Initial cure (3 months
after treatment) was defined as follows: for ulcers, complete
scarring of lesion(s) and disappearance of inflammatory signs;
for nodular lesions, flattening and the absence of infiltration
or other sign(s) of inflammation. Unresponsiveness was defined
as the absence or incomplete scarring of lesion(s) and/or the
persistence of inflammatory signs 3 months after treatment or
the worsening of existing lesion(s) or the appearance of new
lesion(s) 3 months after treatment. Relapse was defined as
the reappearance of an ulcer or nodule and/or local signs of
inflammation after initial cure. Treatment failure was defined
as unresponsiveness or relapse. Cure was defined as initial cure
without relapse 12 months after treatment.
Parasite isolation and biopsy handling. Parasite samples
(lesion aspirate samples and/or biopsy samples) were collected.
Aspirate samples were cultured in Tobie blood agar medium
[14] at 23C. Mass cultures were harvested and cryopreserved
for species identification. DNA was extracted by use of the
QIAmp DNA Mini Kit (Qiagen) or by the classic phenol/chlo-
roform method. For biopsy samples, frozen specimens were lysed
at 65C for 3 h in 50 mL of TNE buffer (25 mmol/L Tris, 100
mmol/L NaCl, and 5 mmol/L EDTA [pH 8]) containing 5%
sodium dodecyl sulfate and 200 mg/mL proteinase K. After ethanol
precipitation, DNA pellets were resuspended in 15 mL of buffer
TE (10 mmol/L Tris and 1 mmol/L EDTA [pH 7.4]) [15].
Parasite species identification. Leishmania species typing
was performed by multilocus polymerase-chain-reaction (PCR)
restriction fragment–length polymorphism (RFLP) analysis.
The target genes rDNA ITS, gp63, hsp70, H2B, and cpb were
amplified and digested as reported elsewhere [15–17]. Restric-
tion patterns were resolved by capillary electrophoresis (2100
Bioanalyzer system; Agilent Technologies) in a microchip device
(DNA 1000 LabChip; Caliper Technologies) or by use of 12%
polyacrilamide at 29:1, with silver stain. Obtained patterns were
compared with those of reference strains of L. (V.) braziliensis
(MHOM/PE/02/PER002), L. (V.) guyanensis (MHOM/BR/78/
M5378), L. (V.) lainsoni (MHOM/PE/03/PER167), L. (V.) pe-
ruviana (MHOM/PE/90/HB22), and L. (Leishmania) amazo-
nensis (MHOM/BR/73/M2269).
Statistical analysis. The response variable in the analysis
was the clinical outcome, defined as cure or failure at the 6-
to 12-month follow-up time point after completion of SbV
therapy. By means of multiple logistic regression analysis, the
1848 • JID 2007:195 (15 June) • Arevalo et al.
Figure 1. Geographic distribution of Leishmania (Viannia) braziliensis, L. (V.) peruviana, and L. (V.) guyanensis by department in Peru. The value
inside each symbol corresponds to the no. of isolates of a given species encountered in each department.
odds of treatment failure were modeled considering the Leish-
mania species as the main predictor of interest. Other recorded
variables that may act as confounding factors were included in
the base model: (1) assumed species-independent variables—
the patient’s age, sex, occupation, and place of infection (Andes
vs. Amazon); (2) assumed species-nonindependent variables—
number of lesions, lesion type, duration of lesions, and total
area of lesions; and (3) the source of SSG (Colombian vs.
Indian). The best final model included age, number of lesions,
duration of lesions, and the source of SSG as significant co-
variates. After adjustment for covariates, a separate comparison
was performed for L. (V.) guyanensis versus L. (V.) braziliensis
or L. (V.) peruviana infections. Absolute failure proportions
and the 95% confidence intervals (CIs) were calculated on the
basis of a binomial distribution. Statistical tests were performed
under a 5% significance level, using STATA software (version
9.0; StataCorp).
RESULTS
A total of 171 patients received a diagnosis of leishmaniasis
and had the infecting species of Leishmania typed during the
study period. Of these patients, 56 did not meet eligibility cri-
teria: 14 had previously received treatment for leishmaniasis,
18 presented concomitant mucosal involvement, 10 did not
complete the first round of SbV treatment, and 14 presented
an unclear clinical outcome (i.e., follow-up of !6 months).
Twelve patients treated with meglumine antimoniate (Glucan-
time) or generic SSG from Peru (Marfan) were also excluded
from the analysis, because they were too few in number for
statistical comparison. Of the 103 patients enrolled in the study,
79 and 24 patients had Leishmania parasites isolated and typed
from skin lesion aspirate and biopsy samples, respectively.
Geographic distribution of characterized Leishmania species.
The geographic distribution of the selected Leishmania isolates
covered all of the Peruvian territory in which leishmaniasis has
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Figure 2. Proportion of pentavalent antimonial treatment failure by
Leishmania (Viannia) species in Peru: for L. (V.) braziliensis, 30.4% (95%
confidence interval [CI], 10%–50%; isolates); for L. (V.) peruviana,np 23
24.5% (95% CI, 10%–40%; isolates); and for L. (V.) guyanensis,np 49
8.3% (95% CI, 0%–20%; isolates). CIs were calculated on thenp 24
basis of a binomial distribution. *Leishmania species that presented a
significant difference in proportion of treatment failure ( ).P ! .05
Table 1. Differential response by Leishmania species to chemotherapy in cutaneous
leishmaniasis.
Leishmania species
Region of
endemicity
Chemotherapeutic
response, % of cure
ReferenceSbV Miltefosine
L. (Viannia) braziliensis Brazil 50.8 … [18]
L. (V.) guyanensis Brazil 26.3 … [18]
L. (V.) braziliensis Guatemala 96.0 … [19]
L. (Leishmania) mexicana Guatemala 57.0 … [19]
L. (V.) braziliensis Peru 69.6 … Present study
L. (V.) peruviana Peru 75.5 … Present study
L. (V.) guyanensis Peru 91.7 … Present study
L. (V.) panamensis Colombia … 91.0 [20]
L. (V.) braziliensis Guatemala … 33.0 [20]
L. (L.) mexicana Guatemala … 60.0 [20]
NOTE. SbV, pentavalent antimonials.
been reported. The 3 most prevalent Leishmania species were
L. (V.) peruviana ( isolates [47.6%]), L. (V.) guyanensisnp 49
( [23.3%]), and L. (V.) braziliensis ( [22.3%])np 24 np 23
(figure 1). Five isolates of L. (V.) lainsoni (4.9%), 1 of L. (L.)
mexicana (1%), and 1 of a putative hybrid, L. (V.) braziliensis/
L. (V.) peruviana (1%), were also identified, but the corre-
sponding patients were not considered in further analyses. The
L. (V.) peruviana isolates originated mainly from the Andean
region, whereas those of L. (V.) braziliensis presented a wide
distribution with a major occurrence along the sylvatic part of
the country. L. (V.) guyanensis was mainly isolated from patients
infected in the central high jungle.
Treatment failure according to Leishmania species. Of the
96 patients infected with L. (V.) braziliensis, L. (V.) peruviana,
or L. (V.) guyanensis, 21 (21.9%) did not respond to treatment.
The proportions of treatment failure were 30.4% in patients
infected with L. (V.) braziliensis (7/23), 24.5% in those infected
with L. (V.) peruviana (12/49), and 8.3% in those infected with
L. (V.) guyanensis (2/24) (figure 2).
On multiple logistic regression analysis, patients infected with
L. (V.) guyanensis were significantly less likely to experience SbV
treatment failure than were patients infected with L. (V.) brazil-
iensis (odds ratio [OR], 0.07 [95% CI, 0.007–0.8]; ). NoPp .03
significant difference was found regarding the odds of treatment
failure when L. (V.) guyanensis infection was compared with L.
(V.) peruviana infection (OR, 0.4 [95% CI, 0.04–4.7]; )Pp .5
or when L. (V.) braziliensis infection was compared with L. (V.)
peruviana infection (OR, 0.3 [95% CI, 0.06–1.3]; ).Pp .1
Finally, we pooled the data on patients infected with either
L. (V.) braziliensis or L. (V.) peruviana and compared them with
the data on patients infected with L. (V.) guyanensis. Again,
albeit not statistically significant, infection with L. (V.) guy-
anensis was associated with a lower proportion of treatment
failure (OR, 0.2 [95% CI, 0.02–1.2]; ).Pp .07
DISCUSSION
In the present study, we assessed the influence that Leishmania
(V.) species has on the outcome of SbV therapy in patients with
CL in Peru. Our data support there being a significant asso-
ciation between the infecting Leishmania species and treatment
outcome. The proportion of treatment failure in patients in-
fected with L. (V.) braziliensis was significantly much higher
than that in patients infected with L. (V.) guyanensis, after
adjustment for potential confounding factors.
The influence of Leishmania species on treatment outcome
has been documented with different drugs in different regions
of endemicity (table 1). Our finding of a higher probability of
therapeutic failure in patients infected with L. (V.) braziliensis
than in those infected with L. (V.) guyanensis contrasts with
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the report of Romero et al. [18], in which the proportion of
treatment failure after 6 months of antimonial therapy (Glu-
cantime) was significantly higher in patients infected with L.
(V.) guyanensis (73.7%) than in those infected with L. (V.)
braziliensis (49.2%). Notably, the proportion of patients in-
fected with L. (V.) guyanensis who experienced SbV treatment
failure was ∼9-fold higher in the Brazilian report than in ours
(73.7% vs. 8.3%, respectively). This observation contrasts with
the closer proportions of SbV treatment failure in patients in-
fected with L. (V.) braziliensis in both studies (49.2% vs. 30.4%,
respectively). Therefore, the discrepancy between these reports
specifically concerns patients infected with L. (V.) guyanensis.
Different factors associated with parasites, host responses, or
treatments—or a combination of these factors [21]—could ex-
plain the contrasting findings.
Some Leishmania species are known to present differing in-
trinsic susceptibility to antimonials [22]. We recently found
clinical isolates of L. (V.) braziliensis and L. (V.) guyanensis that
were either susceptible or highly tolerant to SbV [23]. Accord-
ingly, one might assume that the proportion of SbV-tolerant L.
(V.) guyanensis isolates might vary geographically and explain
the differences in treatment outcome encountered with this
species between Brazil and Peru. However, in our previous
report, we did not find any correlation between parasite SbV
susceptibility (as measured in the in vitro amastigote-macro-
phage model) and treatment outcome [23]. Furthermore, 2
patients infected with L. (V.) guyanensis showed a definite cure
(after follow-up during 12 months), despite being infected with
parasites highly tolerant to SbV [23]. This highlights the need
for comparative multicentric and multidisciplinary studies ad-
dressing both the host and the parasite, with standardized pro-
tocols and definitions.
Our results also provided an updated insight into the dis-
tribution of Leishmania species in Peru. A previous report from
1998 [3] was based on multilocus enzyme electrophoresis.
Globally, this report and the present study are in agreement,
such as the relevant finding of sympatric circulation of L. (V.)
braziliensis and L. (V.) guyanensis in the east-central region of
the Andes (Departments of Junin, Huanuco, San Martin, and
Ucayali). Two specific differences, however, exist. First, the re-
ported proportion of L. (V.) guyanensis isolates from the de-
partments mentioned above increased from 25% (1986–1993)
to 55% (2001–2004). Second, some species were encountered
in unexpected regions, such as L. (V.) peruviana in the Ama-
zonian jungle and L. (V.) braziliensis in the Andes. Differences
in study design might explain this variation in frequency; in
particular, part of our species identification was performed di-
rectly on patient biopsy samples, avoiding the selection biases
introduced by isolation and in vitro maintenance. However,
comparison of both reports might be indicative of a real change
in epidemiological patterns, a phenomenon that is well de-
scribed in Latin America [24]. Altogether, these results em-
phasize the need to conduct continuous prospective studies in
Peru as well as in many other countries of the subcontinent.
In conclusion, our study demonstrates the complex and dy-
namic epidemiology of ATL in Peru, a situation that probably
occurs in other countries of Latin America. Furthermore, the
link between Leishmania species and treatment outcome high-
lights the relevance of incorporating species typing to improve
the clinical management of patients. Moreover, species typing
is needed for epidemiological surveys conducted within control
programs and for clinical trials. Thus, rapid and very specific
methods for parasite identification are urgently needed. PCR-
based genotyping methods, such as multilocus PCR-RFLP
analysis [15] and multilocus sequence typing [25], have been
developed and can be applied directly to biopsy samples. Nev-
ertheless, they are still too cumbersome to be applied in areas
of endemicity that lack sophisticated equipment. Simplification
of these characterization tools is needed for their clinical use
in endemic regions in which several Leishmania species can
coexist (as is the case in Central and South America) but also
in travel medicine, in which a clinician can be confronted with
different species and the geographic location cannot be used
as the only criterion for species discrimination.
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